T2 Biosystems | 8-K: Current report
T2 Biosystems | 8-K: Current report
T2 Biosystems | DEF 14A: Definitive information statements
T2 Biosystems | 8-K: Signing of Loan Agreements
T2 Biosystems | PRE 14A: Preliminary proxy statements relating to merger or acquisition
T2 Biosystems | 8-K: Amended and Restated 2014 Stock Incentive Plan
T2 Biosystems | 8-K: Current report
T2 Biosystems | 8-K: T2 Biosystems Plans To Licence Its Know-How To Expand Its Share Of The Global Market
T2 Biosystems | DEF 14A: Definitive information statements
T2 Biosystems | PRE 14A: Preliminary proxy statements relating to merger or acquisition
T2 Biosystems | 8-K: Current report
T2 Biosystems | 8-K: T2 Biosystems to Host Q3 2024 Earnings Conference Call
T2 Biosystems | 8-K: T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems | 8-K: T2 Biosystems Receives Fda Approval to Market T2candida Panel to Paediatric Patients
T2 Biosystems | 8-K: T2 Biosystems Announces Update on New Product Development Pipeline
T2 Biosystems | S-3: Registration statement for specified transactions by certain issuers
T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement
T2 Biosystems | S-3: Registration statement for specified transactions by certain issuers
T2 Biosystems | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(2)
T2 Biosystems | 8-K: Entry into a Securities Purchase Agreement